On Aug. 28, 2020, Gilead Sciences announced the FDA expanded the Emergency Use Authorization (EUA) enabling use of the investigational antiviral Vekluryﾮ (remdesivir) to treat all hospitalized patients with COVID-19, in addition to the previous authorization for patients hospitalized with severe COVID-19.

The expanded EUA is based on results from the Phase 3 SIMPLE trial evaluating Veklury in hospitalized patients with moderate COVID-19 pneumonia, as well as results from the National Institute of Allergy and Infectious Diseases ACTT-1 trial in hospitalized patients with a range of disease severity.